Dr. Manal Elnenaei, MBChB, MSc, PhD, FRCPath
Chief of Service in Clinical Chemistry, NSHA; Associate Professor, Dalhousie University
Nova Scotia Health Authority; Dalhousie University, Halifax, NS.
Myeloma tumor banking, Myeloma genomic and epigenomic pathways
Effect of reflexive testing on early diagnosis of pituitary disease to improve patient outcomes
Appropriate interpretation of dynamic function tests in endocrinology
Appropriate test utilization to reduce unnecessary waste to the health system
Myeloma Tumor Bank and Genomics Research
Dr. Elnenaei led the Myeloma Tumor Bank and Database initiative in 2016 and brought together a multidisciplinary team comprising Dalhousie Faculty as well Clinician Scientists (Dalhousie Myeloma Research Group), to focus on translational research in Multiple Myeloma. Objectives of this research include a joint focus on clinical genomics and immunogenomics in myeloma leveraging our unique, multidisciplinary expertise to create faithful models of cancer, establish and test new treatment modalities.
This team is currently working on novel and effective genomic diagnostic/prognostic platforms for myeloma patients to replace the more expensive outsourced FISH studies. The first phase of this project has shown promising results. Further work on specific mutation and gene expression panels will also be part of the latter as well as inform immunogenomic and other drug discovery models towards precision medicine.
Previous research that included her PhD at the Institute of Cancer Research in London, UK, focused on the genetic characterization of multiple myeloma on which she had several peer reviewed publications.
Other research projects:
Dr. Elnenaei is also the lead and co-lead investigator on a number of projects within the field of endocrine medicine as well as laboratory test utilization, including physician scorecard models.
Involvement with BHCRI to date:Dr. Manal Elnenaei is an Associate Member of BHCRI
Contact:Department of Pathology & Laboratory Medicine, 5788 University Avenue, Room 616, Halifax, Nova Scotia, B3H 1V8
Elnenaei M, Minney D, Clarke DB, Kumar-Misir A, Imran SA. Reflex and reflective testing strategies for early detection of pituitary dysfunction. Clin Biochem. 2018; 54:78-84
Munro V, Elnenaei M, Doucette S, Clarke DB, Imran SA. The effect of time of day testing and utility of 30 and 60?minute cortisol values in the 250?mcg ACTH stimulation test. Feb 16 2018;54:37-41
Elnenaei MO , Campbell SG , Thoni AJ, Lou A , Crocker BD, Nassar BA An effective utilization management strategy by dual approach of influencing physician ordering and gate keeping. Clin Biochem. 2016;49:208-12.
Elnenaei MO, Heneghen MA, Moniz C. Life-threatening hyperkalaemia and multisystem toxicity following first time exposure to cocaine. Ann Clin Biochem. 2011 Nov 23.
Elnenaei MO, Alaghband-Zadeh J, Sherwood R, Awara MA, Moniz C, Le Roux CW. Leptin and IGF1; diagnostic markers of re-feeding syndrome and mortality. Br J Nutr. 2011 May 4:1-7.
Elnenaei MO, Chandra R, Moniz C. Genotyping of VDR and ER predicts response to oral calcium and vitamin D and correlates with results of NMR pattern recognition- an observational study. Br J Nutr. 2010 Aug; 23:1-8.
Elnenaei MO, Musto R, Alaghband-Zadeh J, Moniz C, Le Roux CW.Postprandial bone turnover is independent of calories above 250 kcal. Ann Clin Biochem. 2010 Jul;47: 318-20
Elnenaei MO, Gruszka-Westwood AM, A'Hernt R, Matutes E, Sirohi B, Powles R, Catovsky D. Gene abnormalities in multiple myeloma;the relevance of TP53, MDM2, and CDKN2A. Haematologica. 2003 May;88:529-37.
Elnenaei MO, Hamoudi RA, Swansbury J, Gruszka-Westwood AM, Brito-Babapulle V, Matutes E, Catovsky D. Delineation of the minimal region of loss at 13q14 in multiple myeloma. Genes Chromosomes Cancer. 2003 Jan;36:99-106.
Jain P, Giustolisi GM, Atkinson S, Elnenaei MO, Morilla R, Owusu-Ankomah K, Rafiq-Mohammed F, Matutes E, Wotherspoon A, Catovsky D. Detection of cyclin D1 in B cell lymphoproliferative disorders by flow cytometry. J Clin Pathol. 2002 Dec;55:940-5